BioSpace News Archive

Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week ® 2023.

ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced the opening of the Company’s 21,500 square foot Good Manufacturing Practices (GMP) facility in Los Angeles, California.

Catalent, Inc. today announced that it will be delaying the release of its third fiscal quarter results and investor conference call, previously scheduled for Tuesday, May 9, 2023.

MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ therapeutics to treat an array of endocrine disorders, announced management will participate in the following investor conferences.

Agile Therapeutics, Inc., a women’s healthcare company, announced it will report first quarter 2023 financial results after the market close on Thursday, May 11, 2023.

Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15th, 2023, at 2:00 p.m. ET / 11:00 a.m. PT in New York City.

Cue Biopharma, Inc. announced that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023.

Alimera Sciences, Inc. announces that it will report first quarter financial results on May 15, 2023, prior to the market open.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of a European patent, numbered 3865189, entitled, “Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment.”

Aprea Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response pathways, announced the appointment of Gabriela Gruia, M.D. to its Board of Directors, effective as of May 5, 2023.